P155 Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases
R. Amihai1, T. Mishael2, S. Grisaru-Granovski2, B. Koslowsky2, G. Abitbol2, E. Goldin2, A. Bar-Gil Shitrit2
1Hadassah-Hebrew University Medical Center, Department of Obstetrics and Gynecology, Jerusalem, Israel, 2Shaare Zedek Medical Center, Department of Obstetrics and Gynecology, Jerusalem, Israel
Inflammatory bowel diseases (IBDs) are commonly diagnosed in reproductive-aged women and can substantially affect pregnancy outcomes. Non-invasive monitoring of IBD during the prenatal course is particularly challenging as traditional laboratory biomarkers are often affected by pregnancy-related physiologic changes. We aimed to evaluate the role of fecal calprotectin (FC) in monitoring disease activity and predicting relapse among IBD women throughout gestation.
Women with IBD attending a multidisciplinary clinic for the preconception, antenatal and postnatal treatment were prospectively recruited during 2014–2018. FC levels were determined with an enzyme-linked immunoassay.
A total of 265 FC (preconception,
FC appears to be a reliable marker of ongoing disease activity throughout the prenatal course as well as a predictor of imminent disease flare among IBD pregnant patients.